Raf

Raf kinases

Raf kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes. RAF is an acronym for Rapidly Accelerated Fibrosarcoma. Raf kinases participate in the RAS-RAF-MEK-ERK signal transduction cascade, also referred to as the mitogen-activated protein kinase (MAPK) cascade. Activation of RAF kinases requires interaction with RAS-GTPases. The three RAF kinase family members are: A-Raf, B-Raf, C-Raf (Raf-1). The B-Raf protein is involved in sending signals inside cells, which are involved in directing cell growth. It was shown to be faulty (mutated) in some human cancers. C-RAF or even Raf-1 is an enzyme that in humans is encoded by the RAF1 gene. The c-Raf protein is part of the ERK1/2 pathway as a MAP kinase kinase kinase (MAP3K) that functions downstream of the Ras subfamily of membrane associated GTPases. C-Raf is a member of the Raf kinase family of serine/threonine-specific protein kinases, from the TKL (Tyrosine-kinase-like) group of kinases.

Raf Inhibitors

(Z)-GW 5074

Cat. No.: HY-10542A

(Z)-GW 5074 is a compound which interacts with both **mHTT (mutant huntingtin protein)** and **LC3**, but not but not with the wild-type HTT protein. (Z)-GW 5074 inhibits **c-Raf**, shows no effect on autophagy, and is effective for neurodegenerative disorder.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AD80

Cat. No.: HY-101963

AD80, a multikinase inhibitor, inhibits **RET**, **RAF**,**SRC**and **S6K**, with greatly reduced mTOR activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Agerafenib

(CEP-32496; RXDX-105)

Cat. No.: HY-15200

Agerafenib (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhibitor of **BRAF^{V600E}** with a K_d of 14 nM.



Purity: 99.53%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ 628

Cat. No.: HY-11004

AZ 628 is a **pan-Raf** kinase inhibitor with **IC_{50}**s of 105, 34 and 29 nM for **B-Raf**, **B-RafV600E**, and **c-Raf-1**, respectively.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AZ304

Cat. No.: HY-117273

AZ304 is an ATP-competitive dual **BRAF** kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with **IC_{50}**s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (**IC_{50}**, 6 nM), CSF1R (**IC_{50}**, 35 nM).



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

B-Raf IN 1

Cat. No.: HY-18227

B-Raf IN 1 is a potent and selective **B-Raf** kinase inhibitor with an IC_{50} of 24 nM.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

B-Raf inhibitor 1

Cat. No.: HY-14177

B-Raf inhibitor 1 is a potent **Raf** kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf^{WT}, B-Raf^{V600E}, and C-Raf, respectively.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

B-Raf inhibitor 1 dihydrochloride

Cat. No.: HY-14177A

B-Raf inhibitor 1 dihydrochloride is a potent **Raf** kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf^{WT}, B-Raf^{V600E}, and C-Raf, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Belvarafenib

(HM95573; GDC-5573; RG6185)

Cat. No.: HY-109080

Belvarafenib (HM95573) is a potent and pan **RAF** (Rapidly Accelerated Fibrosarcoma) inhibitor, with **IC_{50}**s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF^{V600E} and C-RAF respectively.



Purity: 98.05%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Belvarafenib TFA

(HM95573 TFA; GDC-5573 TFA; RG6185 TFA)

Cat. No.: HY-109080A

Belvarafenib TFA (HM95573 TFA) is a potent and pan **RAF** (Rapidly Accelerated Fibrosarcoma) inhibitor, with **IC_{50}**s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF^{V600E} and C-RAF respectively.



Purity: >99.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

BI-882370

Cat. No.: HY-107779

BI-882370 is a potent and selective **RAF** kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BRAF inhibitor

Cat. No.: HY-10247

BRAF inhibitor is a **B-Raf** inhibitor extracted from patent WO/2011103196 A1, Compound P-0850.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

CCT196969

Cat. No.: HY-12846

CCT196969 is a pan-Raf inhibitor, which inhibits **B-Raf**, **BRaf^{V600E}** and **CRAF** with **IC$_{50}$**s of 0.1, 0.04, and 0.01 μM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dabrafenib

(GSK2118436A; GSK2118436)

Cat. No.: HY-14660

Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of **Raf** with **IC$_{50}$**s of 5 nM and 0.6 nM for **C-Raf** and **B-Raf^{V600E}**, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dabrafenib Mesylate

(GSK2118436 Mesylate; GSK 2118436B)

Cat. No.: HY-14660A

Dabrafenib Mesylate is a potent and selective **Raf kinase** inhibitor with **IC$_{50}$**s of 0.6 and 5.0 nM for Raf^{V600E} and c-Raf, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

Doramapimod

(BIRB 796)

Cat. No.: HY-10320

Doramapimod (BIRB 796) is an orally active, highly potent **p38 MAPK** inhibitor, which has an **IC$_{50}$** for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (**K$_d$**=0.1 nM). Doramapimod also inhibits **B-Raf** with an **IC$_{50}$** of 83 nM.



Purity: 99.88%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Encorafenib

(LGX818)

Cat. No.: HY-15605

Encorafenib (LGX818) is a highly potent **BRAF** inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF^{V600E} (**EC$_{50}$**=4 nM).



Purity: 99.63%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

GDC-0879

Cat. No.: HY-50864

GDC-0879 is a potent and selective **B-Raf** inhibitor with an **IC$_{50}$** of 0.13 nM.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

GW 5074

Cat. No.: HY-10542

GW 5074 is a potent and selective **c-Raf** inhibitor with **IC$_{50}$** of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HG6-64-1

(HMSL 10017-101-1)

Cat. No.: HY-12291

HG6-64-1 is a potent and selective **B-Raf** inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a **IC$_{50}$** of 0.09 μM on B-raf V600E transformed Ba/F3 cells.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

L-779450

Cat. No.: HY-12787

L-779450 is a potent and selective **B-Raf** kinase inhibitor with a K_d of 2.4 nM.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lifirafenib

(BGB-283)

Cat. No.: HY-18957

Lifirafenib (BGB-283) is a novel and potent **Raf** Kinase and **EGFR** inhibitor with **IC_{50}** values of 23 and 29 nM for recombinant $BRaf^{V600E}$ and EGFR, respectively.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LUT014

Cat. No.: HY-111940

LUT014 is a **B-Raf** inhibitor with an **IC_{50}** of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 .



Purity: 97.19%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LXH254

Cat. No.: HY-112089

LXH254 is a potent **B/C RAF** inhibitor extracted from patent WO2018051306A1, Compound A.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

LY3009120

(DP-4978)

Cat. No.: HY-12558

LY3009120 is a pan **RAF** inhibitor which inhibits $BRAF^{V600E}$, $BRAF^{WT}$ and $CRAF^{WT}$ with **IC_{50}**s of 5.8, 9.1 and 15 nM, respectively.



Purity: 99.01%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCP110

Cat. No.: HY-123673

MCP110 is an inhibitor of **Ras/Raf-1** interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ML786 dihydrochloride

Cat. No.: HY-14979A

ML786 dihydrochloride potent and orally bioavailable **Raf** inhibitor, with **IC_{50}**s of 2.1, 4.2, and 2.5 nM for **^{V600E}ΔB-Raf**, **wt B-Raf**, and **C-Raf**, respectively. ML786 dihydrochloride also inhibits **Abl-1**, **DDR2**, **EPHA2**, **KDR**, and **RET** (**IC_{50}**=<0.5, 7.0, 11, 6.2, 0.8 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PLX-4720

Cat. No.: HY-51424

PLX-4720 is a potent and selective inhibitor of **$B\text{-}Raf^{V600E}$ with IC_{50} of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for $B\text{-}Raf^{V600E}$ than wild-type B-Raf.**.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

PLX7904

Cat. No.: HY-18997

PLX7904 is a potent and selective **BRAF** inhibitor, with **IC_{50}** of appr 5 nM against $BRAF^{V600E}$ in mutant RAS expressing cells.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PROTAC B-Raf degrader 1

Cat. No.: HY-111758

PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of **B-Raf**. With anti-cancer activity.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

RAF265

(CHIR-265)

Cat. No.: HY-10248

RAF265 is a potent **RAF/VEGFR2** inhibitor.



Purity: 99.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RAF709

Cat. No.: HY-100510

RAF709 is a potent, selective, and efficacious **RAF** inhibitor with **IC_{50}**s of 0.4 nM and 0.5 nM for **BRAF** and **CRAF**, respectively. Antitumor efficacy.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Regorafenib

(BAY 73-4506)

Cat. No.: HY-10331

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1**, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib Hydrochloride

(BAY 73-4506 hydrochloride)

Cat. No.: HY-13308

Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Regorafenib monohydrate

(BAY 73-4506 monohydrate)

Cat. No.: HY-10331A

Regorafenib monohydrate (BAY 73-4506 monohydrate) is a multi-target inhibitor for **VEGFR1/2/3**, **PDGFRβ**, **Kit**, **RET** and **Raf-1** with **IC_{50}**s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ro 5126766

(CH5126766)

Cat. No.: HY-18652

Ro 5126766 (CH5126766) is a first-in-class dual **MEK/RAF** inhibitor that allosterically inhibits **$BRAF^{V600E}$**, **CRAF**, **MEK**, and **BRAF** (IC_{50}: 8.2, 56, 160 nM, and 190 nM, respectively).



Purity: 97.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RRD-251

Cat. No.: HY-117737A

RRD-251 is an inhibitor of **retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction**, with potent anti-proliferative, anti-angiogenic and anti-tumor activity.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 5 mg

SB-590885

Cat. No.: HY-10966

SB-590885 is a potent **B-Raf** inhibitor with **K_i** of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Sorafenib

(Bay 43-9006)

Cat. No.: HY-10201

Sorafenib (Bay 43-9006) is a potent and orally active **Raf** inhibitor with **IC_{50}**s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively. Sorafenib is a multikinase inhibitor with **IC_{50}**s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for **VEGFR2**, **VEGFR3**, **PDGFRβ**, **FLT3** and **c-Kit**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sorafenib (D3)

(Bay 43-9006 (D3))

Cat. No.: HY-10201S

Sorafenib D3 (Bay 43-9006 D3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC_{50}s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sorafenib (D4)

(Bay 43-9006 (D4)) Cat. No.: HY-10201S1

Sorafenib D4 (Bay 43-9006 D4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC_{50}s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sorafenib Tosylate

(Bay 43-9006 Tosylate) Cat. No.: HY-10201A

Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active **Raf** inhibitor with IC_{50}s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

TAK-580

(MLN 2480; BIIB-024) Cat. No.: HY-15246

TAK-580 (MLN 2480) is an orally active and selective inhibitor of **pan-Raf** kinase.



Purity: 99.89%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAK-632

Cat. No.: HY-15767

TAK-632 is a potent **pan-RAF** inhibitor with IC_{50} of 1.4, 2.4 and 8.3 nM for **CRAF**, **$BRAF^{V600E}$**, **$BRAF^{WT}$**, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TBAP-001

Cat. No.: HY-136567

TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a **pan-RAF kinase** inhibitor, with an IC_{50} of 62 nM in BRAF V600E kinase assay.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Vemurafenib

(PLX4032; RG7204; RO5185426) Cat. No.: HY-12057

Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of **B-RAF** kinase, with IC_{50}s of 31 and 48 nM for RAF^{V600E} and c-RAF-1, respectively. Vemurafenib induces cell **autophagy**.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

ZM 336372

Cat. No.: HY-13343

ZM 336372 is a potent inhibitor of the protein kinase **c-Raf**. The IC_{50} value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.



Purity: >96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg